What's new? Log in Free sign up

Filing search / Entero Therapeutics, Inc. / "Safety"

Search information

Entero Therapeutics, Inc.

Companies

"Safety"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

138 results

Newest first Best match first

ENTO Entero Therapeutics, Inc.

Quarterly report

. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. -41- Table of Contents ITEM 4. MINE SAFETY DISCLOSURES Not applicable. ITEM 5. OTHER INFORMATION None

13 Nov 24

7:15am

ENTO Entero Therapeutics, Inc.

Entry into a Material Definitive Agreement

efficacy and safety. For more information about Entero Therapeutics, visit www.enterothera.com and connect on X and LinkedIn. Mayo Clinic has … with similar Pharmacokinetics (PK), and safety profile to traditional ADC; Enabling facile creation of multiple product opportunities with a single

ENTO Entero Therapeutics, Inc.

Quarterly report

registration under 4(a)(2) of the Securities Act. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. -41- Table of Contents ITEM 4. MINE SAFETY DISCLOSURES

21 Oct 24

7:31am

ENTO Entero Therapeutics, Inc.

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

the safety of 1200 mg of latiglutenase has been shown to be comparable to lower doses in previous Phase 2 trials, we believe the higher dose

ENTO Entero Therapeutics, Inc.

Preliminary revised proxy

efforts are focused on therapy, disease management, and food safety. ImmunogenX has patented formulations related to the use of Latiglutenase … safety. ImmunogenX has patented formulations related to the use of Latiglutenase a targeted oral biotherapeutic for celiac disease designed

17 Jun 24

5:23pm

hs1peiwo3uprpaty

Quarterly report

14 May 24

5:26pm

Entry into a Material Definitive Agreement

Independent Auditor’s Report

29 Mar 24

4:16pm

63w5t36db6nw3nw

29 Mar 24

4:16pm

Additional proxy soliciting materials

udepqakf8vvmt52lict

Additional proxy soliciting materials

dh1e9dlfgmrtp65sb0t

Additional proxy soliciting materials

Additional proxy soliciting materials

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease

lbiuub7ymgbhe1u vxba

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease

6evzcs5me kw6ubp2

First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering

6jte6dmj0yk 6pdh8

Prospectus supplement for primary offering

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.